• Several proprietary products developed and ready to market in Canada, California and global markets
• Cannabis product sales expected to generate significant revenue
• Pivot’s IP portfolio includes global patents to cement its leading position in the cannabis industry

On April 4, 2018, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) published an update on the advancements of its industry-leading cannabis product pipeline (http://ibn.fm/leP8x). A newly developed 1% cannabidiol (CBD) oral micelle solution, created in collaboration with the company’s German technology partner, Solmic GmbH, is ready to market. The development of two topical creams using Pivot’s patented formulation and delivery systems is also complete. This formulation will be used to treat a variety of indications, including chemotherapy-induced nausea and vomiting.

Following this development, Pivot anticipates launching several products in Canada when nationwide legalization of cannabis officially begins this summer. The company also expects to begin sales of these products in California during Q3 2018, along with the launch of its proprietary line of ‘Ready-to-Infuse-Cannabis’ (RTIC) natural health products. Sales of bulk powder, stick packs and capsules are expected to generate significant revenue.

Pivot’s current patents provide a critical opportunity for the company to create proprietary products that will be unmatched in quality by other licensed producers and product distributors. Pivot’s intellectual property (IP) portfolio covers several key patents that have demonstrated their ability to deliver pharmaceutical-grade products in clinical trials. The company is ready to manufacture and commercialize its product pipeline in expectation of cannabis legalization in Canada and in regulated international markets.

Pivot’s distinctive business model entails acquiring disruptive drug formulation and delivery technologies, followed by the development of reproducible bio-cannabis products for consumers. The company’s patent-protected products provide significant industry advantages. In accordance with the policy of the World Intellectual Property Organization (WIPO), Pivot’s patents will provide exclusive rights while enabling the company to establish a strong market position and deliver higher returns on investment. They also present opportunities to license or sell inventions and establish a strong position to negotiate with companies that may infringe upon patented rights.

In a news release, Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated, “Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products.”

Pivot Pharmaceuticals is focused on the development and commercialization of cannabinoid-based therapeutic pharmaceutical and nutraceutical products using proprietary drug delivery platform technologies. The research, development and commercialization of products is conducted by the company’s wholly owned subsidiary, Pivot Green Stream Health Solutions Inc. (PGS).

PGS has acquired global rights to BiPhasix™ transdermal drug delivery, Thrudermic transdermal nanotechnology, Solmic oral solubilization and RTIC oil-to-powder technologies. These technologies are used in the development of cannabinoid, CBD and tetrahydrocannabinol (THC) based products. The company’s product development pipeline includes PGS-N001, a candidate for the topical treatment of female sexual dysfunction. Other candidates in the pipeline include PGS-N005 for the treatment of psoriasis and PGS-N007 for cancer supportive care.

Pivot Pharmaceuticals’ development program is well on track toward cementing the company’s position in the cannabis industry. The company’s proprietary pharmaceutical and nutraceutical products are set to establish themselves as leaders in their respective areas of application.

For more information, visit the company’s website at www.PivotPharma.com

• Increasing electric vehicle output drives lithium demand
• Room to grow, with electric vehicle segment still less than one percent of auto market
• QMC Quantum Minerals is one of just a handful of North American lithium miners

With over one million electric vehicles now crisscrossing roads around the globe, it’s going to take more than a bunny beating a drum to keep them going. If the 70 kWh battery pack inside the Tesla Model S is anything to go by, each EV of around the same size will require about 60-65 kilograms (132-143 lbs.) of lithium. That’s an awful lot of lithium, and, even though reserves of the mineral are more than adequate, getting it out in time is posing a problem. As a result, North American automakers are scrambling to ensure security of supply and may soon be turning to QMC Quantum Minerals Corp. (TSX.V: QMC) (FSE: 3LQ) (OTC: QMCQF). The junior exploration company is preparing to mine lithium at Cat Lake, Manitoba. The Irgon Lithium Mine Project property hosts several rare-element granitic pegmatite occurrences, one of which is the Irgon Lithium Mine Dike. The Irgon Dike has a published, historical, non NI43-101 compliant, near surface resource of 1.2 million tons of 1.51 percent Li2O.

Demand for lithium continues to grow, driven by increasing adoption of electric vehicles and the ubiquitous use of portable devices such as smartphones, tablets, laptops and fitness watches. The metal is an essential component of the batteries that provide power for these devices. A lot of this lithium comes from South America in an area known as the ‘Lithium Triangle’ because of the three countries – Argentina, Bolivia and Chile – that comprise it. This Lithium Triangle is estimated to hold over half of the world’s reserves, but current production methods mean that supplies come to market slowly.

The lithium there occurs in underground reservoirs of brines, and, to extract it, the brines are pumped into ponds where, through natural solar heat and atmospheric action, the water evaporates. Since the process requires hardly any output of energy, it is very cost-effective. However, it takes time; evaporation can take months. Consequently, lithium demand always seems to be outstripping supply. Supplies from mineral ore sources might be just the answer. In the past, lithium has been extracted from spodumene, lepidolite and petalite. Notably, the ores at QMC Quantum Minerals’ Irgon Property are pegmatite occurrences rich in spodumene.

The Irgon Dike and several other known pegmatite dikes are situated on 13 adjoining mineral claims covering 6,538 acres, which comprise the Irgon Lithium Mine Property. The property lies within the east-trending Mayville-Cat-Euclid Greenstone Belt (MCEGB) located along the northern contact of the Maskwa Lake Batholith. This northern greenstone belt has a similar structural geological setting to the Bird River Greenstone Belt (BRGB), which is located along the southern contact of the same batholith and is parallel to and approximately 18 km to the south of the MCEGB. The property is located 20 km north of the Tanco Mine Property. The BRGB hosts the world-class Tanco rare element-bearing pegmatite dike. The Tanco Mine went into production in 1969 and produced tantalum, cesium and lithium concentrate. It was previously North America’s largest and sole producer of spodumene, tantalite and pollucite.

As EV production kicks into top gear, demand for lithium is set to grow quickly, particularly in North America, where less than one percent of vehicles are currently electric. With over 200 million diesel and gasoline models to be replaced in the coming years, lithium producers appear to have a clear road to success ahead.

For more information, visit the company’s website at www.QMCMinerals.com

• E-commerce market expected to grow from $2.3 trillion in 2017 to $4.88 trillion by 2021
• Point-of-sale market expected to reach $116 billion by 2025
• Net Element’s new service, Fast Pass Funding, reduces funding times to as little as three hours

Global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) announced on April 5, 2018, that its Unified Payments subsidiary has launched a same-day funding service, called Fast Pass Funding, through its proprietary Netevia platform (http://ibn.fm/Z5UQ6).

Fast Pass Funding is just one of many value-added services available to merchants through Net Element’s Netevia platform. The Fast Pass Funding service will enable eligible merchants to receive funding in as little as three hours during regular business days. This is a vast improvement on the previous average funding times of between 12 and 24 hours. Fast Pass Funding is also delivered to merchants using Aptito, Net Element’s proprietary cloud-based restaurant point-of-sale and management system.

Other value-added services offered through the Netevia platform include fast, easy merchant account opening and integration, payment conversion optimization, over 150 risk-monitoring filters and highly competitive pricing for payment acceptance services. In a recent news release, Vlad Sadovsky, president of Integrated Payments for Net Element, said, “We are pleased to take advantage of the latest capabilities provided by our new Netevia platform and we are excited about the additional upcoming features this platform will bring to us this year.”

With a focus on supporting electronic payments acceptance in a multi-channel environment, including point-of-sale, e-commerce and mobile devices, Net Element was ranked as one of the fastest-growing companies in North America by Deloitte’s 2017 Technology Fast 500™. The company offers a platform for payments-as-a-service transactions and value-added services to small to medium enterprises (SMEs) in the United States and other targeted emerging markets. The company aims to grow transactional revenue in the U.S. through innovative SME productivity services. These will be driven by blockchain technology in combination with Aptito, Net Element’s cloud-based restaurant and retail point-of-sale solution. Internationally, emerging markets with diverse banking, regulatory and demographic conditions will be offered Net Element’s omni-channel platform to deliver flexible payment solutions.

According to Grand View Research (http://ibn.fm/zzxgk), the global market for point-of-sale terminals is on pace to reach $116 billion by 2025, with a CAGR of 9.9 percent. Indications are that more and more consumers will turn to mobile device payment solutions in preference to plastic bankcards. This is driven by transactional speed and convenience, as well as the greater security offered by mobile payments. Net Element intends to take full advantage of the global growth of e-commerce and the surge in demand for wireless technologies in an effort to extend its global reach and grow its business.

Having reached $2.3 trillion in 2017, the worldwide e-commerce market is expected to more than double to reach $4.88 trillion by 2021 (http://ibn.fm/ZdtLR). To capitalize on this phenomenal growth, Net Element intends to develop innovative technologies to complement its Fast Pass Funding solution to service this market sector and integrate emerging business trends like blockchain technology. Jonathan Fichman, a director on the board of Net Element, added, “The company’s recently announced plans to create a blockchain payments platform and its recently released next generation cloud-based point of sale payments system will both be impactful innovations for the industry.”

For more information, visit the company’s website at www.NetElement.com

• DehydraTECH™ has been shown to improve the taste, smell, bioabsorption and bioavailability of high performance ingestible consumer products
• Lexaria is working to eliminate negative side effects and enhance the healthy benefits of a variety of bioactive compounds
• Research being conducted for healthier oral ingestion of vitamins, nicotine and opioids

DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range of commercial applications. LXRP is the only company in the world that has been awarded a patent for the improved (oral or ingestible) delivery of all non-psychoactive cannabinoids in the U.S. and Australia, and the company has 40 more patents pending worldwide. DehydraTECH™ is patented or patent pending for use with a broad range of bioactive molecules. There are many potential uses for this technology, which aims to enhance ingestible products in terms of taste, smell, speed of action, bioabsorption and bioavailability.

The process by which compounds are processed with LXRP’s DehydraTECH™ creates a flavorless, odorless product. Due to this process, manufacturers can avoid the use of artificial sweeteners and still provide a low-sugar, low-calorie product that’s void of unpleasant tastes. Using a variety of long and medium chain fatty acids, this technology allows for the control of when and how the product is absorbed into the body. The tech speeds up the absorption method, delivering the product to where it is needed. Though high-tech, the method is cost-effective, and, due to its increased potency, it requires smaller quantities to incorporate into food, beverages and pills.

The commercial applications of DehydraTECH™ reach beyond cannabinoids. This oral product format allows for a healthier alternative to smoking or vaping practices for both cannabis and nicotine users. The use of this technology for nicotine users holds the potential to shift demand away from smoking cigarettes. The primary cause of illness and death for smokers is not the nicotine, but rather the toxins and carcinogens in the tobacco smoke. LXRP is seeking third-party partnerships within the tobacco industry in order to eliminate the need to light up (http://ibn.fm/1wlln).

In addition, this technology is being used to help deliver fat-soluble vitamins and non-steroidal anti-inflammatory agents (NSAIDs) into orally ingestible products with a greater absorbency and higher performance. The commercial applications are promising as LXRP tests ways to combat the negative side effects and enhance the healthy benefits of a variety of bioactive compounds. While previous studies have focused primarily on cannabinoid applications, LXRP is conducting research for other bioactive compounds such as vitamins, nicotine and NSAIDs.

For more information, visit the company’s website at www.LexariaBioscience.com

• Strategic decision to achieve differentiation leads to Blue Ocean opportunity
• Providing pathways to wealth for entrepreneurs
• Corporate expansion to accommodate international growth

With established roots in the travel industry, Sharing Services, Inc. (OTC: SHRV) sought out a better way to lower costs and achieve differentiation. Rather than employing the highly competitive and exceptionally costly advertising campaigns run by scores of travel companies, Sharing Services aligned innovation with utility, price and cost positions to create uncontested market space and make competition irrelevant. This bold ‘Blue Ocean Strategy’ has engendered a paradigm shift – not just in travel, but across a broad swath of home-based entrepreneurship.

Now a diversified holdings company with global reach, Sharing Services owns, operates or controls interest in a variety of companies specializing in direct selling, and it is re-shaping how entrepreneurs succeed. Sharing Services’ complementary companies either sell products to the consumer directly through independent representatives or offer services that range from travel benefits to health and wellness, energy, technology, insurance services, training and media.

Sharing Services is nurturing a growing international network of home-based entrepreneurs, called ‘Elepreneurs’, that share the company’s collective products and services. The company’s first convention in Dallas attracted participants from the U.S., Canada, Mexico, Singapore and Hong Kong. These legions of home-based entrepreneurs are engaged and excited because of the broad range of beneficial products and services and the boundless opportunities of the program.

Sharing Services provides wholesale travel opportunities and programs that empower families to vacation more often and at a much lower cost. To enhance overall wellbeing, the company provides popular health and wellness products. Sharing Services also offers a vast array of insurance benefits ranging from auto, home and life to health care discounts. The company delivers financial benefits and rewards opportunities through its unique compensation and reward programs, creating pathways to wealth for its entrepreneurs. Sharing Services supports its entrepreneurs and reinforces its message through live seminars and training events, elevating the skills and knowledge of entrepreneurs.

To facilitate its global designs, Sharing Services recently expanded its corporate footprint and moved to a 10,000 square foot facility in Plano, Texas. The new corporate facilities provide the needed space for a growing customer service department and product fulfillment, as well as opportunity and training rooms. The company also recently signed a joint venture agreement to expand its brand and market its products throughout Asia.

Blue Ocean Strategy asserts that companies can succeed by creating ‘blue oceans’ of uncontested market space, as opposed to ‘red oceans’ where competitors bloody the water in a fight for dominance. By making calculated and strategic decisions to achieve differentiation, companies can create a surge in value for buyers and employees while unlocking vast new demand and making competition irrelevant. Leaning on these guiding principles, Sharing Services may be on the cusp of a Blue Ocean tsunami.

For more information, visit the company’s website at www.SharingServicesInc.com, or contact Investor Relations directly at 714-203-6717.

• ETST will investigate combination drugs that combine a mineral element with full spectrum cannabinoid industrial hemp oil; it anticipates completion of white paper studies in early 2019, with clinical trials to follow
• Goal is to produce both an OTC nutraceutical product and a cannabinoid companion generic drug to fight the epidemic of opioid dependency
• Foundations Wellness Center reports that two million Americans are now addicted to opioids

Earth Science Tech, Inc. (OTC: ETST) has set 2019 as the crucial year when the company anticipates completion of white paper studies and the start of human clinical trials to investigate the synergies of drugs that are intended to treat opioid dependency. It intends to test the effectiveness of combination drugs that contain a mineral element and full spectrum cannabinoid industrial hemp oil (http://ibn.fm/cL4Q0).

The clinical trials are expected to commence in 2019 or later. The goal is to produce an over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug to battle opioid dependency. The Foundations Wellness Center reported that two million Americans were addicted to opioids in 2015, the most recent full year for which those statistics are currently available (http://ibn.fm/pyT1D).

The trials are likely to investigate the synergies between mineral elements and cannabinoid industrial hemp oil for use as a treatment for opioid dependency. ETST could then be positioned to bring new products to the marketplace. Per company reports, one drug could be designed to reduce the cravings of opioid addicts and the other, a generic, could make the treatment more effective and reduce the danger of side effects.

Addiction can lead to death from opioids. The Washington Post quotes two specialists as saying that the final death count relating to opioid addiction in 2017 could reach 50,000, higher than the number of AIDS deaths at the peak of that epidemic (http://ibn.fm/iSbs6).

ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets, as well as conducting R&D for medical devices. It is a company that holds several operational subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; and KannaBidioiD, Inc. In addition, the company holds a Montreal-based subsidiary, Canna Inno Laboratories, Inc., providing access to Canadian grants.

For more information, visit the company’s website at www.EarthScienceTech.com

• Record product sales growth reported for fourth quarter and full year 2017
• Company has over 300 of its ultra-high pressure instruments in research labs worldwide
• 2017 revenue exceeded $2.2 million with just one field sales rep; company’s field sales force expanded to five with recent hires
• December 2017 acquisition of high pressure IP allows company to enter the biologics contract research services sector
• Newly-issued patents in Ultra Shear Technology (UST) address broad markets for stable, water-soluble nanoemulsions, including cannabinoids

As scientific researchers who work with cellular material seek to uncover new potential for creating vaccines and drugs, counteracting harmful chemicals and making the therapeutic properties of nutraceuticals and pharmaceuticals more effective, Pressure BioSciences Inc. (OTCQB: PBIO) is watching its development of pressure-based laboratory tools and related consumable products gain a growing worldwide following. Pressure BioSciences’ products are based on the notion that using high pressures to break open cells in order to tap their potential for medicinal and therapeutic uses is a more productive, beneficial way of extracting the biomolecules inside, as compared to traditional methods of ‘beating up’ cells that are commonly employed in research. The company expects recent product development, company acquisitions and personnel decisions to drive it toward a banner year in 2018.

“We have about 300 instruments already placed in research labs all over the world. These instruments generate pressures from levels of several hundred pounds per square inch (“psi”) all the way up to, believe it or not, 90,000 psi,” CEO Ric Schumacher said in a March interview with Uptick Newswire (http://ibn.fm/2HdWm). “They basically are pressure chambers that sit on a laboratory bench, which then offer scientists who are working to find new cures and preventive strategies a very safe way to generate pressures that can be used to kill viruses and bacteria for safer handling, to better control reactions in scientific experiments and to more efficiently break open cells to get to the biomolecules, such as DNA and proteins, that will enable new discoveries.”

Pressure BioSciences’ patented pressure cycling technology (“PCT”) platform uses alternating cycles of hydrostatic pressure ranging between normal levels and the super-high extremes of which its equipment is capable to safely control bio-molecular interactions in the laboratory setting in a manner that complies with the good manufacturing practices (“GMP”) expected of biotherapeutics drug makers by regulatory agencies such as the FDA. That includes the ability to generate downloadable data reports on its processes designed to help ensure consistent outcomes and regulatory compliance. The company’s equipment also generates constant, or static, pressure as part of its applications in such areas as biomarker discovery and scientific forensics, but the company’s PCT platform is the revolutionary (and patented) aspect of its business enterprise.

As Pressure BioSciences has developed new software for its recently released, next generation PCT instrument and acquired new customers throughout the world in recent months, it has also increased its sales force. Schumacher said that reaching a multi-million dollar revenue level just wasn’t possible with the single sales representative that the company has employed for the past 10 years, so it hired four additional field sales reps to cover the entire United States. Even with the new sales reps just hired and trained, the fourth quarter and full year 2017 marked record sales periods, with instrument sales soaring by 55 percent in Q4 and consumable sales up 30 percent for the 12-month period.

“Our instruments are selling well, but what’s also important is that the consumables are also showing good growth— it’s one thing to sell the razor, but you also have to sell the razor blade,” Schumacher said by way of example. “This was by far the largest increase we’ve ever had year over year for the combination of instruments and consumables.”

The company is also excited about its acquisition of Colorado-based high pressure biotechnology company BaroFold, Inc., which gave Pressure BioSciences eight new patents and extends the reach of some of its other patents for another decade. Schumacher said that BaroFold “ran into some problems” with its operation, but he believes that Pressure BioSciences can revive its productivity and take it to the next level.

“All of their intellectual property relates to high pressure and its effect on biomolecules; furthermore, their high pressure applications work on our equipment. We don’t have to build anything new, we don’t have to modify anything,” he said. “Their technology is basically a way of making protein (drugs) better. This acquisition has opened up a whole new business unit for Pressure BioSciences.”

With the BaroFold acquisition and the new developments in Ultra Shear Technology (including two issued patents), Pressure BioSciences now has three distinct working groups — its research products and services unit, its biologics contract research services unit and its Ultra Shear Technology (UST) development unit.

The UST platform incorporates a novel technique based on the use of intense shear forces generated from ultra-high pressure valve discharge, which the company believes can drive a number of commercially important areas including the preparation of extended shelf-life ‘clean label’ food and the formulation of high-quality, stable nanoemulsions that are mixtures of two or more liquids that normally would not mix with each other without the addition of chemicals called emulsifiers. Nanoemulsions are expected to provide an advanced way of making drugs more bioavailable to the body, and they were recently touted as a way to potentially improve the effectiveness of cannabinoids such as CBD in medical marijuana applications (http://ibn.fm/NHw1E).

“With these new initiatives firmly in place, a priceless global customer base, a newly released next-generation instrument with GMP-compliant software, additional key opinion leader customers, greatly enhanced sales and marketing capabilities, and our new BaroFold and Ultra Shear Technology (UST) programs, we look forward with excitement to 2018, which we believe should be a solid year of growth and expansion,” Schumacher said in a news release issued on March 13.

For more information, visit the company’s website at www.PressureBioSciences.com

• Demand for cobalt as component in lithium batteries climbs
• Present cobalt sources mainly located in Africa
• First Cobalt is largest North American explorer focused on cobalt
• Recent drill results promise profitable commercialization

In mining, the lament is often ‘good depth, pity about the size’ or ‘good size, pity about the depth’, since what determines high-grade mineralization is always related to the depth and size of the intersection. Arguably, size may be a weightier factor. Mining technology today has advanced to the point where excavation at the most abysmal depths is commercially feasible. The Kennecott Copper Mine, an open-pit mine near Salt Lake City, Utah, is at 0.6 miles (0.97 km) deep and 2.5 miles (4 km) wide, the largest and deepest excavated hole in the world.

However, while deep holes may make the record books (Kennecott, also known as the Bingham Canyon Mine, was designated a National Historic Landmark in 1966), miners naturally prefer to find their minerals closer to the surface. Thus, drill results like those announced by junior exploration company First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) augur well. Assay results from the Woods Extension Zone of Cobalt South in the Canadian Cobalt Camp confirm cobalt mineralization extending over a broad area that includes 0.47 percent cobalt in one hole and 0.77 percent cobalt in another (http://ibn.fm/ZH4Xp). Such rich mineralization, in samples found at depths of less than 150 meters, certainly increases the possibility of profitable commercialization.

First Cobalt’s drill results signal significant cobalt potential in the Woods Extension Zone. The company has identified broad breccia areas not previously seen at either the Frontier or Keeley Mines, and new fault zones continue to be discovered. Cobalt mineralization has been confirmed in two different structures at relatively shallow depths that may extend to surface. As a result, the company’s 2018 exploration program will be focused on identifying potential targets in the Cobalt Camp that could be amenable to open-pit mining.

First Cobalt is the largest landowner in the Cobalt Camp of Ontario, Canada, a region that includes the historically significant Keeley-Frontier mine, the Haileybury mine and the Bellellen mine. The company controls over 10,000 hectares of prospective land and 50 historic mines, as well as a mill and the only permitted cobalt refinery in North America capable of producing battery materials. It began drilling in the Cobalt Camp in 2017, and the company is seeking to build shareholder value through new discovery and growth opportunities.

Demand for cobalt is expected to continue at elevated levels. The metal is an essential component of lithium-ion batteries, where it is used in the cobalt-oxide cathode. Batteries employing lithium cobalt oxide (LiCoO2) technology can be found in mobile phones, laptops, digital cameras and electric vehicles. Though they are preferred for their high energy density, satisfying demand for cobalt remains problematic. ‘About 90 percent of China’s cobalt originates in the Democratic Republic of the Congo (DRC), where Chinese firms dominate the mining industry’, according to the Washington Post (http://ibn.fm/vIUt8). The largest of these, Zhejiang Huayou Cobalt, supplies ‘some of the world’s largest battery makers.’ However, for over a decade, reports have been surfacing of widespread human rights abuses, both within its operations and throughout DRC-based cobalt mining in general. Moreover, the U.S. Labor Department has listed Congolese cobalt as a product that it suspects is produced using child labor.

These geo-economic forces put First Cobalt in a unique position. The company is the largest exploration company operating in North America that’s focused purely on cobalt. Apart from its properties at the Cobalt Camp, First Cobalt is in the midst of acquiring the Iron Creek cobalt project in Idaho, which is estimated at 1.3 million tons of 0.59 percent cobalt. This may be why the company’s share price has soared by 90 percent, according to Bloomberg (http://ibn.fm/NTX0e).

Recently, First Cobalt announced its inclusion on the 2018 TSX Venture 50, an annual ranking of the top 50 publicly traded companies on the TSX Venture Exchange (http://ibn.fm/O7UOR). The TSX Venture 50 lists the top 10 companies in five major industry sectors, identified as leaders in creating shareholder value based on market capitalization growth, share price appreciation and trading volume. From a total of 1,200 mining companies listed on the TSX Venture Exchange, First Cobalt was ranked fourth on the list of leading mining companies for 2017.

For more information, visit the company’s website at http://ibn.fm/FTSSF

• LXRP recently received a new U.S. patent allowance for ‘composition of matter’ related to its DehydraTECH™ platform’s delivery of cannabinoids; based on past experience, company expects formal granting of patent within 100 days
• Company filed new U.S. patent application for use of DehydraTECH to improve the speed of absorption of active pharmaceutical ingredients through the skin; compared to other commercial formulations, LXRP product exhibited up to a 225 percent increase in permeability
• LXRP gets primary revenue through third party licensing fees related to its proprietary and patented intellectual property; goal is to partner with leading firms globally to deliver best-in-class products, creating greater shareholder value

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) continues to grow its portfolio of worldwide patents related to the use of its DehydraTECH technology for the delivery of cannabinoids to the body. Not only will these patents enable LXRP to commercialize and defend its IP; they are also expected to generate more revenue stemming from licensing agreements with other companies.

LXRP has continued to add to its existing portfolio of patents in the U.S. and Australia in recent months, with more than 40 patents pending in some 40 countries worldwide. The company’s most recent addition is its new U.S. patent allowance for ‘composition of matter’ for DehydraTECH’s delivery of cannabinoids (http://ibn.fm/t97zK). It also filed a U.S. patent application for technology regarding absorption of active pharmaceutical ingredients through the skin (http://ibn.fm/W3PY2).

LXRP is a British Columbia-based, cannabis-focused food bioscience company, and it is a technology disrupter for edible cannabinoids. Its DehydraTECH technology aids in the body’s absorption of cannabinoids.

The company’s most recent patent filing follows successful laboratory evaluation of DehydraTECH in the transdermal delivery of cannabidiol (CBD). Results showed an increase of up to 225 percent in permeability when compared to control formulations from leading commercial penetration enhancers. The company indicates that it will begin third-party licensing discussions for this new transdermal application as soon as possible, and, based upon past experience, it expects the patent to be formalized within 100 days.

In a news release, John Docherty, president of Lexaria, commented on the U.S. patent allowance approval. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties,” he noted.

For more information, visit the company’s website at www.LexariaBioscience.com

• Identifies quality, undervalued real estate investment opportunities with the potential of a high rate of return on investment
• Strategically positioned to serve as a global conduit between the U.S. equity markets and property markets in Switzerland and Northern Europe
• Experienced management team comprised of investment industry experts

American-Swiss Capital, Inc., headquartered in Miami, Florida, is a development-stage company that seeks out superior quality, yet undervalued real estate investment opportunities designed to generate a high rate of return. American-Swiss Capital originated in 2015 with the inspiration that there was a need for a company to be a conduit between the U.S. equity markets and leading enterprises in Switzerland and Northern Europe. American-Swiss Capital’s experienced management team possesses the knowledge and skills required to consistently provide accurate and reliable research specifically designed to identify the safest and most profitable investment opportunities.

The company’s team of investment industry experts have already identified several highly appealing, distressed properties in the sovereign state of Montenegro in southeastern Europe. Montenegro, which presents an attractive business opportunity for foreign investors, is committed to promoting economic development through the government’s Montenegrin Investment Promotion Agency (“MIPA”) that welcomes and encourages foreign investors. Montenegro’s enviable location on the Adriatic Sea includes the fjord-like Bay of Kotor, rugged mountains, glacial lakes, medieval villages, modern cities and gorgeous beaches along its coastline.

Properties located in Montenegro under investment consideration are:

The Tivat Montenegro Property

• An 18-unit apartment beachfront development in the Boka Bay community of Tivat, home to Porto Montenegro and the heart of the coastline’s burgeoning tourism industry. American-Swiss is in negotiations to purchase the property, which was constructed in 2012 but never occupied, for approximately $1.9 million. An independent court surveyor and authorized evaluator expert has valuated the property at approximately $4.5 million. The apartment units range in size from 60-160 square meters. The property has a private beach with a fixed pontoon boat berth situated only 1 kilometer not far from the full-service marina of Porto Montenegro.

The Kovac Gated Community Project

• This nearly 4-acre piece of property, while not in a distressed situation, offers incredible development potential. Located in Tivat on the beautiful, UNESCO-protected Bay of Kotor, about 6.2 kilometers from Porto Montenegro, this property is envisioned as a gated community with the construction of 30 villas, each measuring about 360 square meters (or about 3,875 square feet). American-Swiss estimates the total cost of the project would be approximately $9.3 million, which could be funded by presales and debt financing.

American-Swiss Capital is led by John Karatzaferis, who has served as chief executive officer, secretary and treasurer and as a director since March 2015. Karatzaferis served for 25 years as a consultant for several major organizations, including PeopleCo., AGWS, and NAB Bank in Melbourne, Australia. His experience includes working in the consulting and recruitment fields in both Australia and Europe. For three years, he worked exclusively in debt management and credit control for NAB Bank and NCC in Melbourne, Australia. Karatzaferis received a diploma for accounting and computing.

Robert Sultani has served as a director of American-Swiss Capital since February 2018. Since January 2016, he has been a managing director of RCS Global Services, an international firm providing advisory, audit and training services with respect to the sourcing of natural resources. Sultani works in the Dubai office which serves the Middle East, Africa and Asia, and has worked with clients in the mining, oil and gas, and enterprise software industries. He was a consultant and regional director for the Middle East and Africa for Viziya Corporation and Global PTM, both of which specialize in enterprise resource planning maintenance software and consulting. Sultani has worked in the Middle East region since 1985 with companies in the telecommunications, information technology, petroleum, finance, software and petrochemical industries. He obtained a bachelor’s degree in mechanical engineering from Southeast Missouri State University in 1984.

For more information, visit the company’s website at www.AS-Capital.com